Aranesp
Aranesp Side Effects May Link To Hypertension Lawsuits
Aranesp Side Effects. Aranesp (generic: darbepoetin alfa) is approved to treat anemia caused by chemotherapy. Anemia is a common side effect of chemotherapy, which can damage the production of red blood cells. In anemia, the blood is lacking in healthy red blood cells, which transport oxygen to organs. The FDA approved Aranesp on … [Read more...] about Aranesp Side Effects May Link To Hypertension Lawsuits
Amgen Ends Aranesp Marketing Practices
Amgen Ends Aranesp Marketing Practices. The maker of Aranesp is halting marketing practices that critics said encouraged over-use of the anemia drug. Criticism of the policies, in which Amgen paid rebates to doctors for the purchase of Aranesp, had grown along with questions about the drug's safety. Aranesp is an … [Read more...] about Amgen Ends Aranesp Marketing Practices
Tests Predict if Procrit, Aranesp or Epogen Will Speed Tumor Growth
Study Says Genetic Tests May Predict if Procrit. Some cancer patients treated with the anemia drugs Procrit, Aranesp and Epogen could experience increased tumor growth. However, researcher recently reported that there may be a way to predict which cancer patients are at risk for this devastating side effect. Procrit, Aranesp and … [Read more...] about Tests Predict if Procrit, Aranesp or Epogen Will Speed Tumor Growth
Aranesp Black Box Warning
Aranesp, Epogen, Procrit Black Box Warning. Aranesp, Epogen and Procrit, drugs used to treat anemia in patients undergoing chemotherapy, will soon bear new black box warnings that they may shorten survival time in patients with certain types of tumors. Amgen's Aranesp and Epogen, and Johnson & Johnson's Procrit, have … [Read more...] about Aranesp Black Box Warning
Aranesp, Epogen and Procrit Policy Justified
Aranesp, Epogen, Procrit Policy Justified, More trouble for Aranesp, Epogen and Procrit. Senior Medicare official Dr. Barry Straube said evidence—including two studies—is mounting in the case for cutting the use of controversial anemia drugs sold by Amgen Inc. and Johnson & Johnson. Medicare cut payments for the use … [Read more...] about Aranesp, Epogen and Procrit Policy Justified
Aranesp, Epogen and Procrit Linked to Leukemia in Some Patients
Aranesp, Epogen, Procrit May Cause Leukemia. Aranesp, Epogen and Procrit have been linked to yet another deadly side effect. New research suggests that the anemia drugs, known as erythropoiesis-stimulating agents (ESAs), might play a role in the development of a form of leukemia when they are used to treat people with a … [Read more...] about Aranesp, Epogen and Procrit Linked to Leukemia in Some Patients
Aranesp Lable Changes Warning
Anemia Drug Aranesp Lable Changes. Aranesp, an anemia drug often used to treat chemotherapy patients, could soon have safety information on its label updated yet again, the drug’s maker announced last week. Amgen Inc. announced that it was considering label changes for Aranesp after the results of a study done on breast … [Read more...] about Aranesp Lable Changes Warning
Aranesp Study Shows Little Benefit for Breast Cancer Patients
Aranesp, an anemia drug, does not appear to benefit breast cancer patients. Amgen Inc., maker of Aranesp, recently said interim results from an independent study involving breast cancer patients found Aranesp did not enhance the effect of chemotherapy prior to surgery. The study involved over 700 patients and evaluated whether … [Read more...] about Aranesp Study Shows Little Benefit for Breast Cancer Patients
Controversy over Aranesp, Epogen and Procrit to Be Addressed by FDA Panel
Controversy over Aranesp, Epogen and Procrit. Aranesp, Epogen and Procrit, drugs given to anemia patients suffering end-stage kidney failure, will be taken up by a Food & Drug Administration (FDA) advisory panel tomorrow. Earlier this year, the FDA added a black box warning to the products’ labels recommending that … [Read more...] about Controversy over Aranesp, Epogen and Procrit to Be Addressed by FDA Panel
J&J To Add Warning To Drug
J&J Add Warning To Drug Label. Johnson & Johnson said Monday that it asked European regulators to add a warning to the label of its biotech anemia drug, a move that could benefit a rival product from Amgen Inc. J&J said that the label should warn kidney disease patients not to take Eprex by injection into the … [Read more...] about J&J To Add Warning To Drug
Amgen Attacks J&J Anaemia Drug
Anaemia Drug Safety Concerns. Amgen, the world's largest biotechnology company, is expected on Monday to launch an attack on the safety of an anaemia drug made by its rival Johnson & Johnson, the world's second-largest pharmaceuticals concern. It is unusual for drugs companies to attack each other's products publicly. Amgen's … [Read more...] about Amgen Attacks J&J Anaemia Drug
